Merck’s first quarter results drew a positive market reaction, reflecting operational resilience despite a 1.6% ...

CHICAGO — In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses primary results from ASCENT-04 evaluating sacituzumab govitecan plus pembrolizumab in ...

At the trial’s first pre-specified interim analysis, Keytruda before surgery (neoadjuvant), then continued after surgery (adjuvant) in combination with standard of care (SOC), RT with or without ...

MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, Keytruda (pembrolizumab), for adults with resectable locally advanced head ...

Merck & Co – known as MSD outside the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has been approved by the US Food and Drug Administration (FDA) to treat a new ...

Keytruda is designed to enhance the immune system’s ability to detect and combat tumour cells. This humanised monoclonal antibody prevents PD-1 from interacting with its ligands, PD-L1 and PD-L2, ...

The trial was not designed to isolate the effect of KEYTRUDA in each phase (neoadjuvant or adjuvant) of treatment. The major efficacy outcome measure was event-free survival (EFS) by BICR defined as ...

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers. Studies found patients taking Keytruda can reduce ...

Pharma Merck's Keytruda wins breakthrough head and neck cancer nod around surgery, but with a limitation By Angus Liu Jun 13, 2025 10:50am Merck & Co. Keytruda head and neck cancer PD-1/L1 ...

RAHWAY, N.J., June 13, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® ...

RAHWAY, N.J.-- (BUSINESS WIRE)--Jun 13, 2025--FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued ...

Health and Human Services Secretary Robert F. Kennedy Jr. on Wednesday continued his efforts to alter the government structure supporting immunizations, naming vaccine skeptics and doctors with ...